(Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the ...
06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor ( ...
Find annual and quearterly earnings data for TScan Therapeutics, Inc. Common Stock (TCRX) including earnings per share, earnings forecasts at Nasdaq.com.
This information can be used by investors to verify and understand the financial position of the company. Many, but not all SEC filings are available in the ...
TScan Therapeutics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View TCRX financial statements in full.
People also ask
What does TScan Therapeutics do?
Rating
(4,975)
TScan Therapeutics (TCRX) will release its next earnings report on May 6, 2024. In the last quarter TScan Therapeutics reported -$0.289 EPS in relation to ...
TScan Therapeutics, Inc. (US:TCRX) has 79 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC) ...